下载App
扫码立即下载
  • 下载App

    扫码立即下载

  • 在线客服

    登录后咨询在线客服
+
恭喜您!
成功领取价值超 5000港元/年的高级行情
前往体验 >>
多维分析
公司估值 资金追踪 卖空分析
SGMO Sangamo Therapeutics
4.950
-0.090-1.79%
盘后价
4.95000.00%
显示同比
不显示
隐藏空行
(Q2)2022/06/30(Q1)2022/03/31(FY)2021/12/31(Q4)2021/12/31
Investing cash flow
Cash flow from continuing investing activities
-68.16% 2,842.9万 -96.24% 170.5万 191.37% 2.48亿 140.35% 5,263.5万
Net PPE purchase and sale
25.03% -544.5万 64.29% -283.9万 -58.2% -2,327.8万 28.75% -285.8万
Net business purchase and sale
-- 0 -- 0 83.1% -11.9万 -- 0
Net investment purchase and sale
-64.94% 3,387.4万 -91.48% 454.4万 206.01% 2.72亿 143.96% 5,549.3万
Cash from discontinued investing activities
Investing cash flow
-68.16% 2,842.9万 -96.24% 170.5万 191.37% 2.48亿 140.35% 5,263.5万
Financing cash flow
Cash flow from continuing financing activities
128.31% 2,287.4万 -110.29% -156.7万 -78.54% 3,285.8万 -69.48% 211.2万
Net common stock issuance
233.67% 2,192.9万 -- 0 -80.99% 2,709.9万 -- 0
Proceeds from stock option exercised by employees
-71.28% 113.1万 -95.93% 7.4万 -20.48% 901.7万 -66.5% 238.2万
Net other financing activities
62.12% -18.6万 26.54% -164.1万 -325.88% -325.8万 -40.63% -27万
Cash from discontinued financing activities
Financing cash flow
128.31% 2,287.4万 -110.29% -156.7万 -78.54% 3,285.8万 -69.48% 211.2万
Net cash flow
Beginning cash position
-2.18% 1.22亿 35.79% 1.8亿 62.13% 1.33亿 -31.6% 1.78亿
Current changes in cash
-105.74% -268.2万 -633.08% -5,883.7万 -6.9% 4,780.6万 101.59% 203.3万
Effect of exchange rate changes
-14.47% 13万 167.68% 22.2万 41.16% -26.3万 50% -11.5万
End cash Position
-30.44% 1.19亿 -2.18% 1.22亿 35.79% 1.8亿 35.79% 1.8亿
Free cash flow
0.67% -5,943万 19.2% -6,181.4万 -265.33% -2.57亿 -569.06% -5,557.2万
Investing cash flow
Cash flow from continuing investing activities
-68.16% 2,842.9万 -96.24% 170.5万 191.37% 2.48亿 140.35% 5,263.5万
Net PPE purchase and sale
25.03% -544.5万 64.29% -283.9万 -58.2% -2,327.8万 28.75% -285.8万
Net business purchase and sale
-- 0 -- 0 83.1% -11.9万 -- 0
Net investment purchase and sale
-64.94% 3,387.4万 -91.48% 454.4万 206.01% 2.72亿 143.96% 5,549.3万
Cash from discontinued investing activities
Investing cash flow
-68.16% 2,842.9万 -96.24% 170.5万 191.37% 2.48亿 140.35% 5,263.5万
Financing cash flow
Cash flow from continuing financing activities
128.31% 2,287.4万 -110.29% -156.7万 -78.54% 3,285.8万 -69.48% 211.2万
Net common stock issuance
233.67% 2,192.9万 -- 0 -80.99% 2,709.9万 -- 0
Proceeds from stock option exercised by employees
-71.28% 113.1万 -95.93% 7.4万 -20.48% 901.7万 -66.5% 238.2万
Net other financing activities
62.12% -18.6万 26.54% -164.1万 -325.88% -325.8万 -40.63% -27万
Cash from discontinued financing activities
Financing cash flow
128.31% 2,287.4万 -110.29% -156.7万 -78.54% 3,285.8万 -69.48% 211.2万
Net cash flow
Beginning cash position
-2.18% 1.22亿 35.79% 1.8亿 62.13% 1.33亿 -31.6% 1.78亿
Current changes in cash
-105.74% -268.2万 -633.08% -5,883.7万 -6.9% 4,780.6万 101.59% 203.3万
Effect of exchange rate changes
-14.47% 13万 167.68% 22.2万 41.16% -26.3万 50% -11.5万
End cash Position
-30.44% 1.19亿 -2.18% 1.22亿 35.79% 1.8亿 35.79% 1.8亿
Free cash flow
0.67% -5,943万 19.2% -6,181.4万 -265.33% -2.57亿 -569.06% -5,557.2万
Currency Unit
美元美元美元美元
Accounting Standards
US-GAAPUS-GAAPUS-GAAPUS-GAAP
Audit Opinions
----无保留意见--

FY:Financial Year 年度报告,相当于上市公司向SEC披露的10-K文件。

Q:Quarter 季度报告,相当于上市公司向SEC披露的10-Q文件,其中Q1、Q2、Q3、Q4为单季报,跨度为3个月;Q6、Q9为累计季报,Q6为6个月,Q9为9个月。

环比数据来源于季报,环比 = (本期 - 上期)/上期 * 100%

公司概况 更多
Sangamo治疗公司是一家临床阶段的生物技术公司,致力于锌指蛋白的研究和开发。它集中在三个治疗领域:遗传性代谢性疾病,中枢神经系统,疾病和免疫学,包括炎症性和自身免疫性疾病。它还提供互补的技术平台,如基因治疗、体外细胞治疗、体内基因组编辑和体内基因组调控。该公司由爱德华·O·兰菲尔二世于1995年创立,总部设在加利福尼亚州布里斯班。
CEO: Macrae Ch.B, M.B., MRCP, Ph.D., Alexander D.
所属市场: 纳斯达克
上市日期: 2000/04/06
富途热股榜
美股港股沪深
交易热度搜索热度资讯热度
名称代码最新价涨跌幅

加载中...

自选
回到顶部